Dear Participants
 
We are looking forward to welcoming you to the 32nd Ernst Klenk Symposium 2016 on "Precision oncology: translating basic discoveries into patient survival", taking place from Dec. 08 - 10, 2016.

The aim of the 32^nd Klenk Symposium in Molecular Medicine is to provide a platform for the presentation of the discoveries of basic principles of actionable genomic aberrations in cancer, the development and use of genetically engineered mouse models of cancer, the development of personalized precision medicine approaches, as well as novel approaches in immune therapy.

Cancer treatment is currently witnessing a fundamental paradigm shift. The recent progress in the understanding of the genetic changes, the molecular mechanisms of clonal evolution, the genetics of drug resistance, the cross-talk between malignant cells and the non-malignant stroma, as well as development of drugs interfering with “cancer-specific” targets is considered as an evolving field leading to individualized therapeutic strategies. These developments, commonly referred to as “precision oncology”, will undoubtedly lead to an enhanced survival of our patients in the future.

Charles Swanton (The Francis Crick Institute - London, UK) has accepted our invitation to be the honorary guest speaker of the Ernst Klenk Lecture (Dec. 09, 2016 at 6 p.m.) and acts as the scientific coordinator. As clinician scientist, his research focuses on the understanding of tumor heterogeneity and evolution, as well as on mechanisms of replication stress and mutagenesis. His findings have a huge impact in the field of precision oncology with important implications for the development of innovative approaches for cancer treatment.

Through his outstanding engagement we are excited to present a cutting-edge program with leading international experts. During the four sessions, these experts will present new insights into and discuss the latest advances in the field of precision oncology. We would like to thank all guest speakers for their active participation and engagement.

• Session I: Discovering basic principles of actionable genomic aberrations in cancer/tumor evolution/acquired resistance
  
  
• Session II: Using mouse models as preclinical avatars for the development of precision cancer medicine
  
  
• Session III: Novel approaches for targeted intervention in solid tumors, lymphomas and leukemias
  
  
• Session IV: Immune checkpoint blockade as a novel therapeutic approach


For further information: Klenk Program 2016

The poster session with over 50 posters will give you an excellent opportunity for scientific exchange.

Registration is closed - we appreciate your understanding.
So far we received over 480 registrations. With regard to the capacity of the venue - the Main Lecture Hall of the Medical Faculty - unfortunately, we had to close the registration.

The annual Klenk Symposium is a special biomedical science meeting at the University of Cologne that attracts national and international scientists, physicians and particularly students. The meeting is named in honor of Prof. Ernst Klenk - an outstanding German lipid-biochemist, who headed the Institute for Physiological Chemistry at the Medical Faculty, University of Cologne, from 1936 to 1965. Since its foundation the participation in the meeting is free of charge. Thus, we are thankful for the support provided by the Fritz Thyssen Foundation and the following industrial companies: Bristol-Myers Squibb / Roche / Merck / Janssen Oncology / Lilly / Siemens - New Oncology / Abbvie and Cologne Convention Bureau.

We are expecting a highly interactive meeting sparked by the panel of internationally renown speakers, who will discuss their latest research developments with an audience of scientists and physicians.

We are looking forward to welcoming you and wish all participants who have to travel to Cologne a pleasant journey.

Sincerely yours

We are looking forward to welcoming you!

Yours sincerely

Prof. Dr. Christian Reinhardt
Chair - Cologne Klenk Symposium Board 2016

Prof. Dr. Roman Thomas
Chair - Cologne Klenk Symposium Board 2016

Prof. Dr. Thomas Benzing
Chair - Center for Molecular Medicine Cologne